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Studies of intermittent claudication have shown
that about 25% of patients referred to a peripheral
vascular clinic will deteriorate significantly.1 Some
will receive angioplasty; up to 74% of angioplasties
performed in vascular units are conducted on
patients with claudication.2 Some will progress to
rest pain, ulceration, and gangrene; of these patients,
more than 90% will undergo major amputation,
arterial reconstruction, or angioplasty, procedures
that involve a high risk to the patient and major cost
to the hospital.3
Although factors such as cigarette smoking,4 dia-
betes mellitus,5 systolic blood pressure,6 hyper-
triglyceridemia,6 and low ankle-brachial pressure
index (ABPI)7 have been independently associated
with the deterioration of limb ischemia, the role of
hemorheologic factors in the clinical progression of
peripheral arterial disease is not clear. Subjects with
claudication have consistently demonstrated elevated
plasma levels of several hemostatic and rheologic fac-
tors, including fibrinogen and plasma viscosity.8-12 In
addition, the severity of lower limb atherosclerosis, as
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measured by angiography, has been related to eleva-
tions in plasma fibrinogen and fibrin D-dimer lev-
els.13-15 Interactions between cigarette smoking and
fibrinogen, fibrin D-dimer, and plasma viscosity have
also been reported in subjects with peripheral arter-
ial disease.11,12
To determine whether hemostatic and rheologic
factors have prognostic significance in patients with
intermittent claudication, a cohort study of 607
patients with claudication was established in 1989.
After 1 year of follow-up, an interim analysis found
that fibrin D-dimer was an independent predictor of
deterioration in peripheral arterial disease, as indi-
cated by a fall in ABPI.16 The aim of the current
analysis was to determine whether several hemostat-
ic and rheologic factors were related to progression
of peripheral arterial disease and, in particular, to the
onset of severe chronic leg ischemia. We were also
interested in the confounding effect of cigarette
smoking, (which is a major risk factor for peripheral
arterial disease17 and affects plasma levels of hemo-
static factors, such as fibrinogen) and ABPI, as a
measure of underlying disease.
METHODS
Study population. The study was a follow-up
investigation of 742 consecutive patients who were
diagnosed by a consultant physician as having inter-
mittent claudication at the Peripheral Vascular
Clinic, Royal Infirmary of Edinburgh, between
January 1989 and December 1990. Exclusion crite-
ria were rest pain, ulcer or gangrene, and previous or
impending arterial surgery.
Baseline examination. On entry to the study,
patients completed a self-administered questionnaire
that included validated questions on medical history,
angina, intermittent claudication, smoking history,
and current medication.18 Brachial systolic and dias-
tolic pressures were measured in the right arm using
a Hawksley random zero sphygmomanometer. Ankle
systolic pressures were measured using the Hawksley
random zero sphygmomanometer and a Doppler
probe. The ABPI, which is the ratio of ankle to
brachial systolic pressure, was calculated for each leg
using the posterior tibial pulse, whenever possible.
The lower of these two values was used in statistical
analysis. A 20 ml sample of venous blood was taken
for analysis of hemostatic and rheologic factors and
total cholesterol and random glucose levels. One year
later, patients were invited to undergo a similar
examination, except a blood sample was not taken.
Laboratory tests. Fibrinogen was assayed in cit-
rated plasma according to a thrombin clotting tur-
bidimetric method that was performed with a Coag-
A-Mate (Oreganon Teknika, Cambridge, U.K.) ana-
lyzer. Fibrin D-dimer was measured using a commer-
cial enzyme-linked immunosorbent assay (ELISA)
supplied by AGEN (Parsippany, N.J.). The von
Willebrand factor (vWF) also was estimated using an
ELISA (DAKO, Copenhagen, Denmark), as was tis-
sue-type plasminogen activator (tPA) antigen
(Biopool, Umea, Sweden). Blood and plasma viscosi-
ty were measured in a Coulter-Harkness (Oreganon
Teknika) capillary viscometer at 37° C and high shear
rates. In addition, a microhematocrit was measured
for the blood sample using a Hawksley (Hawksley and
Son Ltd., Lancing, U.K.) microcentrifuge.
Estimation of glucose levels was made with the use of
a Cobas Bio analyzer (Roche Products, Welwyn
Garden City, England) using standard kits. Total cho-
lesterol levels also were estimated on a Cobas Bio ana-
lyzer using the Boehringer-Mannheim Biochemicals
(Indianapolis, Ind.) standard cholesterol kit.
Six-year follow-up. Subjects were followed over
a period of 6 years to determine the incidence of
severe chronic leg ischemia (rest pain, ulceration,
gangrene, and amputation) and peripheral vascular
procedures, including angiography, angioplasty, lum-
bar sympathectomy, and bypass graft operation. The
incidence of ischemic heart disease (IHD; angina and
myocardial infarction) and stroke also were recorded.
The criteria used to diagnose angina, fatal and non-
fatal myocardial infarction, and fatal and nonfatal
stroke were adapted from those of the World Health
Organization (WHO)18 and American Heart
Association.19 The patients were followed until death
or September 1996, when the analysis began.
Each patient’s record was flagged at the Scottish
National Health Service Central Registry, which
ensured that any death certificates were provided
automatically and the cause of death was determined.
In addition, each patient’s hospital record was exam-
ined to confirm that diagnostic criteria for cardiovas-
cular events were fulfilled. All events were allocated a
diagnostic code according to International Classi-
fication of Disease, Version 9 (ICD-9) guidelines.
Information concerning hospital admissions and
discharges was obtained from the Information and
Statistics Division of the Scottish Office. The
Information and Statistics Division provided a com-
puter printout for each listed subject using prespeci-
fied ICD-9 codes for the cardiovascular events. All
reported events were verified by examination of med-
ical records according to the predetermined criteria.
Each patient also was sent a questionnaire in
February 1996 that inquired about any changes in
medical history, new treatment for intermittent clau-
dication, and arterial operations, including angiogra-
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phy during the past 6 years. They also were asked to
record any change in smoking habits and current
medication and to complete the WHO question-
naire on intermittent claudication.18 Information
also was sought on hospital attendances within the
follow-up period.
In addition, each patient’s general practitioner
was contacted and asked to supply information con-
cerning any new vascular event, hospital admissions,
and changes in medication occurring within the past
6 years. Multiple sources of information were used
to ensure that as many events as possible were iden-
tified and subsequently verified. 
Definition of peripheral arterial disease cate-
gories at follow-up. Two groups of patients were
identified: (1) those whose symptoms had deterio-
rated sufficiently to require vascular investigations
but who did not develop severe chronic leg ischemia
during follow-up and (2) a group composed of
those who developed definite symptoms of severe
chronic leg ischemia (i.e., rest pain, ulceration, and
gangrene) during the past 6 years. These categories
were identified by clinical diagnosis from the
patients’ medical records.
Statistical analysis. Data were analyzed with the
use of the University of Edinburgh mainframe com-
puter using the SPSS-X and SAS statistical packages.
Mean or percentage values for baseline risk factor
characteristics were calculated for each of the two fol-
low-up categories of peripheral arterial disease and
compared with values for a group of subjects who had
no cerebrovascular or coronary events or deteriora-
tion of limb ischemia during follow-up. Patients with
IHD and stroke events only were excluded from the
analysis. Differences in median values of each hemo-
static and rheologic factor were tested with the use of
the Kolmogorov-Smirnov test across the two cate-
gories relative to the group who showed no deterio-
ration. Relative risks of the two disease groups for a
unit increase in each of the hemostatic or rheologic
factors were estimated by multiple logistic regression
models that were adjusted for age and sex and then
further adjusted for ABPI and pack-years, which is a
measure of lifetime smoking consumption and is cal-
culated by the average number of packs of cigarettes
smoked per day multiplied by the number of years of
smoking. In the regression analysis, the levels of fib-
rinogen, von Willebrand factor, and pack-years were
all square root transformed, and those of fibrin D-
dimer and tissue plasminogen activator were logarith-
mically transformed due to skewed distributions.
RESULTS
A total of 607 subjects from the baseline cohort
of 742 was followed prospectively for 6 years. One
hundred thirty-five patients were excluded because
they were found to have had rest pain, ulceration,
gangrene, or previous or impending vascular opera-
tion, including angioplasty, at recruitment or
because their medical records could not be traced.
During the 6-year follow-up period, 210 (34.6%)
patients died. Of these, 90 (42.9%) died of IHD, 29
(13.8%) died of stroke, and 27 (12.9%) die of other
vascular causes. There were 62 (29.5%) deaths due to
noncardiovascular causes, and 31 (50%) of these were
due to cancer. The cause of death in 2 patients could
not be determined. A total of 203 (33.4%) subjects
did not have a vascular event or show any deteriora-
tion in limb ischemia. Forty-five patients underwent
investigations or treatment for peripheral vascular dis-
ease; 19 of these (42.2%) underwent femoral angiog-
raphy, 9 (20.0%) underwent femoral angioplasty, 1
(2.2%) underwent iliac angiography, 6 (13.3%)
underwent iliac angioplasty, 1 (2.2%) underwent iliac
embolectomy, 4 (8.9%) underwent aortic angiogra-
phy, and 1 (2.2%) underwent a lumbar sympathecto-
my. Three (6.7%) patients had a femoral bypass graft
operation, and 1 (2.2%) patient had an aortic bypass
graft operation. Although information was not col-
lected on the particular leg requiring intervention, it
is probable that vascular investigations were mostly
performed on the leg for which there was a the lower
ABPI at baseline. None of these patients progressed
to severe chronic leg ischemia or required amputation
during the follow-up period. Four (8.9%) patients in
this category had diabetes mellitus at baseline. There
were eight deaths among the vascular intervention
group; of these deaths, five occurred in patients who
died of cardiovascular disease. 
Sixty-four patients progressed to symptoms of
severe chronic leg ischemia; rest pain developed in
20 (31.3%), leg ulceration developed in 30 (46.9%),
and gangrene developed in 14 (21.9%). Ten patients
(15.6%) within this group had been diagnosed as
being diabetic at baseline. Nineteen patients (29.7%)
subsequently required leg amputation, and 32
(50.0%) died (27 [42.2%] of vascular causes). 
Baseline characteristics of the vascular interven-
tion group and of patients who developed severe
chronic leg ischemia were compared with character-
istics of those who experienced no vascular events
(Table I). The vascular intervention group was sig-
nificantly younger (p ≤ 0.05), had a far higher pro-
portion of males (p ≤ 0.001), and had symptoms of
more severe claudication (grade II) (p ≤ 0.05) than
the group without progression. As expected, the
group that developed more severe symptoms had a
significantly lower ABPI at baseline (p ≤ 0.001) than
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those who did not deteriorate or those who required
vascular intervention. Conversely, the patients with
severe chronic leg ischemia had a lower mean level
of total cholesterol at baseline than the group with-
out events, although none were receiving lipid-low-
ering medication (6.3 mmol/L compared with 6.8
mmol/L, p ≤ 0.001). There was a higher percentage
of current cigarette smokers in this group. There
were no significant differences in lifetime smoking
consumption (pack-years) or random glucose or
blood pressure levels between either of the two
event groups compared with those who showed no
progression, although the mean levels of these fac-
tors were slightly higher in the group of patients
who developed severe chronic leg ischemia.
Table II shows the median levels and interquar-
tile ranges for each hemostatic and rheologic factor
across the two groups of patients whose disease
worsened relative to those who showed no progres-
sion. There were no significant differences in base-
line levels of fibrinogen, vWF, fibrin D-dimer, tPA,
plasma viscosity, or hematocrit between the vascular
intervention group and the comparison group. In
those who underwent vascular investigations, how-
ever, baseline levels of whole blood viscosity were
significantly higher (p ≤ 0.05) than in the group
without progression and also were higher than in the
group with severe chronic leg ischemia. This differ-
ence in blood viscosity partly reflected the higher
plasma viscosity and hematocrit levels observed in
this group. Levels of fibrinogen, whole blood vis-
cosity, and hematocrit tended to be lower in the
group of patients with severe chronic leg ischemia
than in the group of patients without progression.
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Table I. Age, sex, and cardiovascular risk characteristics of patients by category of peripheral arterial dis-
ease progression
No peripheral arterial disease progression Vascular intervention Severe chronic leg ischemia
Factor (n = 203) (n = 45) (n = 64)
Age (yr) 65.1 (0.6) 61.9 (1.3)† 65.3 (1.0)
Sex (% male) 49.5 77.8* 60.9
IC
Grade I (%) 49.8 29.5† 44.9
Grade II (%) 50.2 70.5† 53.1
ABPI 0.59 (0.01) 0.62 (0.03) 0.48 (0.02)*
Systolic pressure (mm Hg) 150.4 (1.8) 147.4 (3.1) 149.2 (3.5)
Diastolic pressure (mm Hg) 82.9 (0.8) 84.3 (1.7) 80.5 (1.5)
Random glucose (mmol/L) 5.6 (0.1) 6.1 (0.1) 6.8 (0.4)
Cholesterol (mmol/L) 6.8 (0.1) 6.7 (0.2) 6.3 (0.2)*
Smoking status (%)
Current 36.5 24.4 43.8
Ex 49.8 71.1 45.3
Never 10.8 2.2 6.3
Pack-years (√) 4.7 (0.2) 4.7 (0.4) 5.0 (0.3)
Values are given in mean (SE) or percent.
IC, intermittent claudication; ABPI, ankle brachial pressure index.
*p ≤ 0.001.
†p < 0.05.
Table II. Median values (interquartile ranges) of hemorheologic factors at baseline by category of periph-
eral arterial disease progression
No peripheral arterial disease progression Vascular intervention Severe chronic leg ischemia
Hemorheologic factor (n = 203) (n = 45) (n = 64)
Fibrinogen (gm/L) 2.74 (2.42-3.15) 2.73 (2.46-3.42) 2.71 (2.36-3.26)
von Willebrand factor (IU/dl) 131.0 (106.0-165.0) 138.0 (100.8-181.3) 154.0* (122.0-187.0)
Fibrin d-dimer (ng/ml) 96.0 (64.5-135.8) 94.5 (57.0-156.8) 97.0 (69.0-168.0)
Tissue-type plasminogen activator (ng/ml) 10.3 (7.9-13.2) 10.4 (8.4-13.2) 11.9 (9.2-13.6)
Whole blood viscosity (mPa/sec) 3.48 (3.06-3.83) 3.75† (3.38-4.13) 3.37 (3.12-3.99)
Plasma viscosity (mPa/sec) 1.38 (1.32-1.45) 1.40 (1.36-1.46) 1.36 (1.30-1.41)
Hematocrit (%) 45.0 (43.0-48.0) 47.0 (45.0-50.0) 46.0 (43.0-48.8)
Kolmogorov-Smirnov test was used to examine differences in distributions between event group and no progression group.
*p ≤ 0.01.
†p ≤ 0.05.
vWF levels were significantly higher (p ≤ 0.01) in
patients who developed severe chronic leg ischemia
compared with the group without events and high-
er than levels of the vascular intervention group.
Table III shows that after adjustment for age and
sex, with the exception of whole blood viscosity (rel-
ative risk, 1.43; 95% confidence interval, 1.06 to
1.92; p ≤ 0.05), there were no significant relation-
ships between any of the factors and the risk of vas-
cular intervention. Further adjustment for lifetime
smoking (pack-years) and baseline ABPI had little
effect on the relationship between whole blood vis-
cosity and risk of vascular intervention (relative risk,
1.44, 95% confidence interval, 1.06 to 1.97, p ≤
0.05). However, after adjustment for smoking and
ABPI, the magnitude of the risks of vascular inter-
vention increased slightly for both fibrinogen and
plasma viscosity and became statistically significant
(p ≤ 0.05). With adjustment for pack-years only, the
relative risk of severe chronic leg ischemia associated
with a unit increase in vWF rose from 1.24 (p > 0.05)
to 1.27 and became statistically significant (p ≤ 0.05)
(data not shown). However, none of the relative risks
of severe chronic leg limb ischemia associated with a
standard deviation or one-unit increase in the
hemorheologic factors were statistically significant
after adjustment for pack-years and ABPI.
DISCUSSION
In this prospective cohort of 607 patients with
claudication, 109 (18%) patients developed clinical
deterioration of limb ischemia over 6 years of follow-
up. The incidence of severe chronic leg ischemia was
approximately 10.5%, which is comparable to that of
some studies7,20 but less than that reported in earli-
er studies in which early intervention techniques,
such as angioplasty, were not readily available.21-24
The high mortality rate associated with severe
chronic leg ischemia reported in these studies was
confirmed in the current study; 50% of these patients
subsequently died, primarily of IHD and stroke. 
We found that baseline levels of fibrinogen,
whole blood viscosity, and plasma viscosity were sig-
nificantly associated with the risk of vascular inter-
vention. There are two possible explanations for
these findings. First, the operation could have been
performed on those with more advanced arterial dis-
ease. However, the baseline ABPI was not signifi-
cantly different in the patients who subsequently
underwent vascular intervention compared with
those who had no evidence of peripheral arterial dis-
ease progression. Second, if viscosity and arterial dis-
ease contribute to limb ischemia,12 it is possible that
surgeons were operating on patients with worsening
symptoms due to increased viscosity.
We are aware of only two other studies that
examined the prognostic significance of rheologic
factors and hemostatic factors in the progression of
intermittent claudication.25,26 The first was based on
a small series of 62 patients, of whom only 8 demon-
strated definite signs of deterioration. The results are
in accord with those of the current study in that fib-
rinogen and whole blood viscosity were significantly
correlated with the deterioration of peripheral arter-
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Table III. Relative risks (95% confidence intervals) of peripheral arterial disease progression for unit
increase in hemorheologic factors after adjustment for age, sex, cigarette smoking, and ABPI
Unit increase in hemorheologic Vascular intervention Severe chronic leg ischemia
factor* Adjusted (n = 45) (n = 64)
Fibrinogen (+0.21√gm/L) a† 1.30 (0.98, 1.74) 1.04 (0.80, 1.34)
b‡ 1.35 (1.01, 1.79)§ 1.02 (0.78, 1.32)
von Willebrand factor (+2.59√IU/dl) a† 1.13 (0.86, 1.48) 1.24 (0.98, 1.57)
b‡ 1.16 (0.89, 1.52) 1.20 (0.93, 1.55)§
Fibrin D-dimer (+1 ln ng/ml) a† 1.22 (0.74, 2.02) 1.35 (0.92, 1.98)
b‡ 1.26 (0.76, 2.09) 1.30 (0.87, 1.95)
Tissue-type plasminogen activator (+1 ln ng/ml) a† 1.13 (0.50, 2.58) 1.61 (0.82, 3.15)
b‡ 1.21 (0.52, 2.82) 1.21 (0.60, 2.41)
Whole blood viscosity (+0.67 mPa/sec) a† 1.43 (1.06, 1.92)§ 1.11 (0.85, 1.45)
b‡ 1.44 (1.06, 1.97)§ 1.04 (0.80, 1.34)
Plasma viscosity (+0.10 mPa/sec) a† 1.35 (0.99, 1.83) 0.81 (0.61, 1.08)
b‡ 1.40 (1.02, 1.91)§ 0.80 (0.59, 1.09)
Hematocrit (+4.72%) a† 1.39 (0.97, 2.02) 1.10 (0.83, 1.46)
b‡ 1.38 (0.94, 2.01) 1.05 (0.79, 2.16)
*Unit increase in hemorheologic factors equates approximately with 1 standard deviation or 1 unit on a logarithmic scale.
†Analyses adjusted for age and sex.
‡Analyses adjusted for age, sex, pack/years, and ABPI.
§p ≤ 0.05.
ial disease, assessed in this instance by changes in
walking distance and flow patterns recorded with
plethysmography.25 In contrast, the ADEP study,
which was a multicenter clinical trial of patients with
claudication who were followed for 18 months,
reported no significant association between fibrino-
gen and peripheral arterial deterioration.26
Elevations in rheologic factors, including fibrino-
gen and plasma and blood viscosity, may have impor-
tant effects on a reduction in arterial blood flow,
which could contribute to atherogenesis and to the
progression of disease.27 In a previous case-control
analysis based on these patients with claudication,
plasma viscosity was associated with the risk of clau-
dication independent of age, sex, and pack-years but
not after adjustment for the ABPI.28 These findings
and those of the current study are consistent with the
hypothesis that elevated blood and plasma viscosity
and fibrinogen (a major determinant of viscosity)
may directly promote symptomatic and progressive
worsening of leg muscle ischemia during exercise due
to reductions in microcirculatory blood flow distal to
arterial stenoses, regardless of the extent of peripher-
al arterial disease.12 In one earlier case-control study,
plasma and whole blood viscosity were also lower in
patients who had developed severe chronic leg
ischemia compared with age-matched population
control subjects.13 Similarly, plasma and blood vis-
cosity, fibrinogen, and total cholesterol levels were
slightly lower in those in the current study in whom
severe chronic leg ischemia subsequently developed. 
Our results also showed that after adjustment for
life-time smoking, vWF was predictive of the future
development of severe chronic leg ischemia. However,
adjustment for smoking history and ABPI reduced the
relative risks to nonsignificance, suggesting that the
relationship between this factor and progression of
claudication is partly accounted for by cigarette smok-
ing and severity of disease at baseline.
The role of vWF in the outcome of peripheral
arterial disease has not been widely investigated. In a
clinical study, vWF was predictive of graft occlusion in
patients who had undergone infrainguinal revascular-
ization.29 The mechanisms through which vWF may
promote thrombosis are unclear. vWF mediates
platelet adhesion to damaged subendothelium30 and
is a cofactor for platelet aggregation at high shear
rates.31 Furthermore, vWF is increased in subjects
with peripheral arterial disease32 and in smokers com-
pared with nonsmokers,33 and it has been suggested
that smoking may be responsible for a major portion
of endothelial dysfunction in peripheral arterial dis-
ease.11 In this study, elevated vWF was associated with
the development of severe chronic leg ischemia, an
association that persisted after adjustment for age, sex,
and smoking history. This could reflect microcircula-
tory endothelial disturbance associated with ischemia
because this is a major source of raised vWF levels.34
However, it is more likely that the raised vWF levels
contributed to occlusive platelet-fibrin thrombi for-
mation in the severely stenosed arteries of these
patients and hence may have promoted the develop-
ment of severe chronic leg ischemia.
We previously reported that after 1 year, fibrin D-
dimer was independently associated with a reduction
in ABPI, which is a measure used to indicate the
extent of arterial narrowing in the legs.16 This asso-
ciation was weaker after a longer follow-up but may
have been related to the small number of patients in
each disease category. The results from the 6-year
follow-up also are not directly comparable to that of
the 1-year follow-up. In the current analysis, because
a change in ABPI could not be assessed, deteriora-
tion of disease was mainly based on symptoms
indicative of clinical progress, the assessment of
which is subjective and known to lack reliability. In
contrast, the ABPI measure used in the first analysis
is a more objective measure of underlying athero-
sclerotic disease and is a continuous variable with
greater power to detect the progression of underly-
ing lower limb atherosclerosis.
It should be noted that the categorization of
these patients by symptoms rather than by an objec-
tive assessment of worsening severity of disease may
have biased the results of this study. We do not know
whether the vascular intervention group had signifi-
cantly deteriorated over the 6-year follow-up or
whether they were merely considered more suitable
for early intervention, given that they were younger
and reported more severe symptoms of claudication
at baseline. The occurrence of vascular intervention
also may have reflected the particular interventional
practice of the treating surgeon. Conversely, it is
plausible that this group represented a pathologically
different group with a slower rate of progression of
peripheral arterial disease than the group of patients
with severe chronic leg ischemia. This is supported
by the finding that more than half of those who had
vascular surgery underwent angiography only but
none progressed to severe chronic leg ischemia. 
In conclusion, we found significant associations
between fibrinogen and whole blood and plasma vis-
cosity and the risk of moderate progression of
peripheral arterial disease. In contrast, elevated levels
of vWF were related to the future development of
severe chronic leg ischemia in patients with claudica-
tion when lifetime cigarette smoking was taken into
account but not when the underlying severity of
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peripheral arterial disease was included. Further
studies are required to assess the predictive value of
such factors in the disease progression of subjects
with peripheral arterial disease. 
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